Present and future challenges in the treatment of haemophilia: The patient's perspective

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Arcieri, Romano ^a   Molinari, Angelo C ^a,b   Farace, Stefania ^a   Mazza, Giuseppe ^a   Garnero, Alberto ^a   Calizzani, Gabriele ^c   Giordano, Paola ^a,d   Oliovecchio, Emily ^e   Mantovani, Lorenzo ^a,f   Manzoli, Lamberto ^a,g   Giangrande, Paul ^a,h  

^a Italian Federation of Haemophilia Societies (FedEmo)   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g UNIVERSITY OF CHIETI   (Italy)

^h Oxford Haemophilia and Thrombosis Centre   (United Kingdom)

Author keywords

Comprehensive care; Factor VIII demand; Haemophilia treatment; Sustainability

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

HEALTH CARE ACCESS; HEMOPHILIA; HUMAN; ITALY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS;

DRUG THERAPY; HEMOPHILIA A; HUMANS;

EID: 84885592271     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.013s     Document Type: Review

References (41)

1. Bolton-Maggs PH, Pasi KJ. Haemophilia A and B. Lancet 2003; 361: 1801-9.
2. Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
3. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009; 101: 674-81.
4. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
5. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8.
6. Carlsson KS, Hojgard S, Lindgren A, et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004; 10: 515-26. (Pubitemid 39317762)
7. Skinner MW. Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. Br J Haematol 2011; 154: 704-14.
8. Calizzani G, Profili S, Candura F, et al. The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus 2013; 11 (Suppl 4): s64-76.
9. Calizzani G, Profili S, Candura F, et al. Plasma and plasmaderived medicinal products self-sufficiency: the Italian case. Blood Transfus 2013; 11 (Suppl 4): s118-31.
10. Calizzani G, Vaglio S, Arcieri R, et al. Models for institutional and professional accreditation of haemophilia centres in Italy. Haemophilia 2013; 19: e248-55.
11. Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia 2008; 14: 361-74. (Pubitemid 351338698)
12. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
13. Franchini M, Mannucci PM. Prophylaxis for adults with haemophilia: towards a personalised approach? Blood Transfus 2012; 10: 123-4.
14. Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus 2012; 10: 169-73.
15. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
16. Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
17. Tagliaferri A. Awaiting evidence-based recommendations on prophylaxis in adult patients. Haemophilia 2010; 16: 955-6.
18. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13: S65-8.
19. Young G. New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program 2012; 2012: 362-8.
20. Giampaolo A, Abbonizio F, Puopolo M, et al. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. Transfus Med 2011; 21(4): 280-4.
21. Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
22. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87: S33-9.
23. Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasmaderived is better. Blood Transfus 2010; 8: 288-91.
24. Franchini M. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8: 292-6.
25. Calizzani G, Arcieri R. Clinical and organisational aspects of haemophilia care: the patients' view. Blood Transfus 2012; 10: 110-1.
26. Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus 2011; 9: 366-70.
27. Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 2012; 119: 4108-14.
28. Mantovani LG, Monzini M, Mannucci PM, et al. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia 2005; 11: 589-97. (Pubitemid 41631593)
29. Schramm W, Gringeri A, Ljung R, et al. Haemophilia care in Europe: the ESCHQoL study. Haemophilia 2012; 18: 729-37.
30. L'uso dei farmaci in Italia - Rapporto OsMed (gennaio - settembre 2012). Roma, gennaio 2013. Osservatorio Nazionale sull'Impiego dei Medicinali. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/rapporto- osmed2012.pdf. Accessed on 21/08/2013.
31. EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States, 24 October 2011. Available at: http://www.EUCERD.eu/upload/file/EUCERDRecommendationCE.pdf. Accessed on 21/08/2013.
32. EUCERD Recommendations on Rare Disease European Reference Networks (RD ERNS), 31 January 2013. Available at: http://www.eucerd.eu/?post-type= document&p=2207. Accessed on 21/08/2013.
33. European guidelines for the certification of Haemophilia Centres, 7 June 2013. Available at: http://www.euhanet.org/docs/Euhanet-European-guidelines-for- the-certification-of-Haemophilia-Centres-2013.pdf. Accessed on 21/08/2013.
34. Baker JR, Crudder SO, Riske B, et al. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health 2005; 95: 1910-6. (Pubitemid 41572360)
35. Calizzani G, Vaglio S, Candura F, et al. The evolution of the regulatory framework of the plasma and plasma-derived medicinal products system in Italy. Blood Transfus 2013; 11 (Suppl 4): s6-12.
36. st century through competitive tendering. Haemophilia 2013; DOI: 10.1111/hae.12169.
37. Gouw SC, Van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. NEJM 2013; 368: 231-9.
38. Hay CR, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
39. Hay CR, Palmer B, Chalmers E et al., on behalf of UKHCDO. The incidence of factor VIII inhibitors in severe haemophilia A following a major product switch in the UK: a prospective, controlled study. Haemophilia 2012; 18: 828.
40. Morgan SG, Thomson PA, Daw JR, Friesen, MK. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy 2013; DOI: 10.1016/j. healthpol.2013.05.022.
41. Garrison LP Jr, Towse A, Briggs A, et al. Performancebased risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013; 16: 703-19.